Evergreen Capital Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.27M | Sell |
25,921
-2,371
| -8% | -$312K | 0.06% | 259 |
|
|
2026
Q1 | $3.94M | Buy |
28,292
+2,545
| +10% | +$356K | 0.09% | 226 |
|
|
2025
Q4 | $3.16M | Buy |
25,747
+398
| +2% | +$48.4K | 0.07% | 243 |
|
|
2025
Q3 | $2.81M | Buy |
25,349
+1,277
| +5% | +$145K | 0.07% | 236 |
|
|
2025
Q2 | $2.67M | Buy |
24,072
+3,393
| +16% | +$361K | 0.08% | 231 |
|
|
2025
Q1 | $2.32M | Sell |
20,679
-109
| -0.5% | -$11.2K | 0.08% | 235 |
|
|
2024
Q4 | $1.92M | Buy |
20,788
+1
| +0% | +$90 | 0.06% | 256 |
|
|
2024
Q3 | $1.74M | Buy |
20,787
+406
| +2% | +$31K | 0.06% | 269 |
|
|
2024
Q2 | $1.4M | Sell |
20,381
-622
| -3% | -$41.5K | 0.05% | 276 |
|
|
2024
Q1 | $1.54M | Sell |
21,003
-1,107
| -5% | -$85.1K | 0.06% | 255 |
|
|
2023
Q4 | $1.79M | Buy |
22,110
+501
| +2% | +$39K | 0.07% | 232 |
|
|
2023
Q3 | $1.62M | Sell |
21,609
-1,689
| -7% | -$130K | 0.07% | 240 |
|
|
2023
Q2 | $1.8M | Buy |
23,298
+2,289
| +11% | +$183K | 0.08% | 226 |
|
|
2023
Q1 | $1.74M | Buy |
21,009
+562
| +3% | +$46.5K | 0.08% | 224 |
|
|
2022
Q4 | $1.76M | Buy |
20,447
+1,323
| +7% | +$105K | 0.08% | 221 |
|
|
2022
Q3 | $1.18M | Buy |
19,124
+14,853
| +348% | +$937K | 0.06% | 249 |
|
|
2022
Q2 | $264K | Buy |
4,271
+671
| +19% | +$41.5K | 0.01% | 456 |
|
|
2022
Q1 | $214K | Sell |
3,600
-1,652
| -31% | -$106K | 0.01% | 593 |
|
|
2021
Q4 | $381K | Sell |
5,252
-432
| -8% | -$29.8K | 0.02% | 420 |
|
|
2021
Q3 | $397K | Buy |
5,684
+1,353
| +31% | +$95.1K | 0.02% | 389 |
|
|
2021
Q2 | $298K | Buy |
4,331
+189
| +5% | +$12.6K | 0.01% | 417 |
|
|
2021
Q1 | $268K | Buy |
+4,142
| New | +$267K | 0.01% | 420 |
|
|
2020
Q3 | – | Sell |
-2,775
| Closed | -$214K | – | 431 |
|
|
2020
Q2 | $214K | Buy |
+2,775
| New | +$213K | 0.02% | 352 |
|
|
2020
Q1 | – | Sell |
-3,665
| Closed | -$238K | – | 426 |
|
|
2019
Q4 | $238K | Buy |
3,665
+358
| +11% | +$23.3K | 0.02% | 397 |
|
|
2019
Q3 | $210K | Buy |
3,307
+153
| +5% | +$10K | 0.02% | 388 |
|
|
2019
Q2 | $213K | Buy |
+3,154
| New | +$207K | 0.02% | 381 |
|
|
2018
Q4 | – | Sell |
-3,070
| Closed | -$237K | – | 391 |
|
|
2018
Q3 | $237K | Buy |
3,070
+187
| +6% | +$14.1K | 0.02% | 328 |
|
|
2018
Q2 | $204K | Sell |
2,883
-8,827
| -75% | -$623K | 0.02% | 336 |
|
|
2018
Q1 | $883K | Sell |
11,710
-40,475
| -78% | -$3.22M | 0.08% | 153 |
|
|
2017
Q4 | $3.74M | Buy |
52,185
+3,025
| +6% | +$230K | 0.38% | 68 |
|
|
2017
Q3 | $3.98M | Buy |
49,160
+6,280
| +15% | +$480K | 0.47% | 61 |
|
|
2017
Q2 | $3.04M | Buy |
42,880
+11,385
| +36% | +$758K | 0.49% | 61 |
|
|
2017
Q1 | $2.14M | Sell |
31,495
-2,680
| -8% | -$188K | 0.45% | 63 |
|
|
2016
Q4 | $2.45M | Buy |
+34,175
| New | +$2.54M | 0.47% | 67 |
|
Other funds holding GILD
Evergreen Capital Management's GILD Position: Q2 2026 in Review
Evergreen Capital Management reduced its Gilead Sciences (GILD) stake by 8.4% in Q2 2026, selling an estimated $312K and leaving 25,921 shares worth $3.27M. The position accounts for 0.06% of the portfolio, ranked #259.
Evergreen Capital Management first reported a position in GILD in Q4 2016 and has held it in 34 quarters since. The position peaked at $3.98M in Q3 2017. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Evergreen Capital Management held 25,921 shares of Gilead Sciences worth $3.27M as of Q2 2026.
- Evergreen Capital Management sold 2,371 Gilead Sciences shares in Q2 2026, an estimated $312K.
- Gilead Sciences made up 0.06% of Evergreen Capital Management's portfolio in Q2 2026, its #259 holding.
- Evergreen Capital Management first reported a position in Gilead Sciences in Q4 2016 and has held it in 34 quarters since.
- Evergreen Capital Management's Gilead Sciences position peaked at $3.98M in Q3 2017.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Evergreen Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.